Original article

Shanta Nibedita Satpathy*


Affiliation:-
Associate Professor, Department of ENT, Hi-Tech Medical College, Bhubaneswar, Odisha, India

The name of the department(s) and institution(s) to which the work should be attributed:
Department of ENT, INHS Ashwini, Colaba Mumbai, Maharastra, India

Address reprint requests to
Dr. Shanta Nibedita Satpathy.
Department of ENT, Hi-Tech Medical College, Bhubaneswar, Odisha, India

Article citation:
Satpathy SN. Role of Immunotherapy: Histaglobulin in Allergic Rhinitis. J Pharm Biomed Sci. 2014; 04(11):967-971. Available at www.jpbms.info

ABSTRACT
Objective: The aim of our study was to improve the quality of life of Allergic Rhinitis patients by giving Histaglobulin injection. Otolaryngologists have been disappointed with the results of various modalities available for the treatment of allergic rhinitis. This problem can be solved with Histaglobulin.
Materials and methods: A study of 50 patients of allergic rhinitis in South Bombay was conducted in the department of ENT and Head and Neck Surgery in INHS Ashwini at Colaba for a period of 18 months. Histaglobulin was administered by subcutaneous injection in doses of 2 cc once a week for 3weeks and follow up was done for 40 weeks.
Results: The effectiveness of Histaglobulin was evaluated by detail history of clinical examination to assess the response to therapy. Twenty three (23) patients had complete response; twenty five (25) had fair response while two (2) patients had a poor response.
Conclusions: The results of Histaglobulin therapy was satisfactory. There was no adverse reaction following the therapy.

KEYWORDS: Allergic Rhinitis; Histaglobulin; Quality of Life.


REFERENCES
1.Parrot, J.L. Histaminolyse at histaminopesive: Actualities pharmacologiques 11th Ser PP. 233-257, Paris Masson 1958.
2.NormanPhilp S., Immunotherapy for nasal allergy, Journal of Allergy clinical Immunology pp.992-996, May 1988.
3.Gelfand, H. herald, cinder Jesus. Grant Sydney F. and Soiffer Maxwell: Evaluation of Histamine – Gammaglobulin in treatment of various allergic conditions, Annals of Allergy,1963;21:150-161.
4.Asokan N.N. and Sukumaran E.M., Gammaglobulin histamine complex in the treatment of allergic disorders of respiratory tract, the Indian Practitioner. 1982;35:171-176.
5.Borodin Y, Egerova Mezhcodava A, The use of Gammaglobulin and Histamine for treating Allergic disease, Rev. allergy ad appl. Immunology, 17.434, 1963.

Source of support: None

Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussing research work. There is no financial conflict with the subject matter discussed in the manuscript.

Copyright © 2014 Satpathy  SN. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Research article

Reyadh Jassim Abbas^1,*,May Al- Sabbagh¹, Dr Hassan Mohammed Abbas Altemmi², Dr Monewer³


Affiliation:-
¹Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi
²Ph.D Clinical Pharmacy, Medical City Baghdad, Baghdad Iraq, 3MSC Oncology Medical City Baghdad, Iraq

The name of the department(s) and institution(s) to which the work should be attributed:
1Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi

Address reprint requests to
Reyadh Jassim Abbas
Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi 

Article citation:
Abbas RJ, Sabbagh-Al M, Altemmi Abaas HM, Monewer. The possible protective effect of melatonin in Iraqi breast cancer patients taking chemotherapy. J Pharm Biomed Sci. 2014; 04(11):1001-1006. Available at www.jpbms.info

ABSTRACT
Breast cancer is the most common cancer that lead to death in the world. The most common type of breast cancer is ductal carcinoma. Chemotherapy that used in the treatment of breast cancer is associated with adverse effects like cardio toxicity, especially with doxorubicin use, due to increase free radical formation like reactive oxygen species. To evaluate the protective effect of melatonin in Iraq breast cancer taking chemotherapy, 40 volunteers, 10 normal subjects served as control, 30 volunteers were divided into two groups randomly first 10 patient named group A taking only chemotherapy without melatonin. The second 20 patient named group B taking melatonin + chemotherapy. In the  current study, we measured serum malondialdehyde (MDA), liver function test (ALT, AST and TSB) and cardiac enzyme (CPK and LDH). The results showed that chemo therapy increase serum MDA, AIT, AST, CPK, LDH and reduction in serum TSB. Patients who taking extra supplement with melatonin (group B) showed normalized of these biochemical parameters. Melatonin has a role in protecting against toxicity that produced by chemotherapy.


KEYWORDS: Breast cancer; Chemotherapy; melatonin.

REFERENCES
1.American cancer society . Breast cancer . Fact and Figure 2009. American cancer society, Atlanta, GA2009.
2.Iraq cancer registry, 2010,p28.
3.Wood, WC  et at. Malignant tumor of breast in ;devitant,Hellman editor.Cancer principle and practice of oncology 7th edition , Philadelphia Pa. Lippincott william and Wilkins, pp77-1415.
4.Chu, E et al . Cancer chemotherapy.In; Katzung BG,editor. Basic and clinical pharmacology, 9th edition . Mc Graw-Hill, pp: 898-930.
5.Stefulj J et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res. 2001;30:243–247.
6.Ackermann K et al. Melatonin synthesis in the human pineal gland .BMC neuroscience. 2007; 8supp1:p2.
7.Pieri C. Melatonin peroxyl radical scavenger more effective than vit. E Life sci. 55(15): PL 271-6.
8.Reitman and frankel. As cited by Bio Merieux kit (france). Am J Clin Path.1957;28:56 .
9.Tietz N.W. text book of clinical chemistry 3rd ed. (1999):1133-1137.
10.Buege, JA, Austa SD. Method enzymol. 1978;51:302-310.
11.Sharhar S. et al. Antioxidant intake and status, and oxidative stress in relation to breast cancer risk: A case-control study. Asian Pac. J. Cancer Prev. 2008;9:343–349.
12.Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313:17-29.
13.A.Nath et al. Elevated lipid peroxidation in breast cancer patients, Journal of pharmacy and biological sciences (JPBS),2001;9(4):17-21.
14.Shaoyu Zhou,et al. Doxorubicin–induce persistent oxidative stress to cardiac myocytes.2001;121:(3):151-157.
15.Ganiyu Oboh et al . Cyclophosphamide- induced oxidative stress in brain. Experimental and Toxicologic Pathology.2014;66(8):351-406.
16.Satoshi Numazawa et al. Possible Involvement of Oxidative Stress in 5-Fluorouracil-Mediated myelosuppression in mice. Basic & Clinical Pharmacology & Toxicology.2011;108(1):40–45.
17.Qi W, Reiter RJ, Tan DX, et al. Inhibitory effects of melatonin on ferric nitrilotriacetate-induced lipid peroxidation and oxidative DNAdamage in the rat kidney. Toxicology.1999;139:81–91.
18.Bateman JR, et al. 5-Fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer. 1971;28:907-913.6
19.Paul D. King et al.Hepatotoxicity of Chemotherapy, The Oncologist.2001;6:162-176.p163.
20.Meredith MJ, Reed DJ. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by Adriamycin and 1,3 chloroethyl-nitrosurea (BCNU). Biochem Pharmacol 1983;32:1383-1388.
21.Deepa PR, Varalakshmi P. Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chemico-Biological Interactions. 2003;146:201-210.
22.Dr. Mustafa Ghazi Alabbassi. Melatonin Ameliorates Hepatic Damage Induced by Cyclophosphamide in rat.
23.Bahir Abdul Razzaq Mshemish et al . Effect of Silymarin against CAF protocol Hepatotoxicity, AJPS, 2011, Vol. 9, No.1.
24.Khalid A Al-Khazragi FRCP. Studying the Effect of Silymarin Against Hepatotoxicity Induced by CAF Protocol in Breast Cancer Women. Iraqi Medical Journal , Volume 56, Number 2, December 2010, ISSN 0304-4564.
25.Kamal Adel Amin,et al . Impact of Breast Cancer and Combination Chemotherapy on Oxidative Stress, Hepatic and Cardiac Markers, Sep 2012:15(3);306-312.
26.Ayça Bilgino?lu, M.D et al. Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Arch Turk Soc Cardiol 2014; 42(3):265-273.
27.Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. http://www.nlm.nih.gov. Drug Saf. 2000 Apr;22(4):263-170.


Source of support: None

Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.


Copyright © 2014 Abbas RJ, Sabbagh-Al M, Altemmi Abaas HM, Monewer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review  article

Preetinder Singh^1,*.,MDS, Ayushi Gandotra².,BDS


Affiliation:-
¹Associate Professor (Periodontology and Oral Implantology) SDD Hospital and Dental College, Barwala, Panchkula (Haryana), India
²Research Associate, Private Practice, Chandigarh,India

The name of the department(s) and institution(s) to which the work should be attributed:
Periodontology and Oral Implantology, SDD Hospital and Dental College, Barwala, Panchkula (Haryana), India

Address reprint requests to
Dr. Preetinder Singh, MDS
Associate Professor (Periodontology and Oral Implantology) SDD Hospital and Dental College, Barwala, Panchkula(Haryana), India

Article citation:
Singh P, Gandotra A. Strategic occupational hazards affecting dental profession and its management: A review. J Pharm Biomed Sci. 2014; 04(11):995-1000. Available at www.jpbms.info

ABSTRACT
Occupational diseases are diseases arising from or out of activity in the workplace. It is resulting from exposure to physical, chemical, biological, psychosocial or ergonomics factors in the workplace. The presence of these factors in the workplace is essential for occupational diseases to occur; e.g.,exposure to lead in the workplace will leads to lead poisoning, and presence of silica in the workplace will cause silicosis. It must be recognized, however, that other factors, such as individual susceptibility, characteristics of exposure to those substances (example duration of exposure, concentration of substance, and condition of the substance) does have a role in the developing of occupational diseases. Occupational diseases of dentistry have, in general, received scant attention. The chief cause of this is lack of awareness among occupational dental physicians. Exposure to various chemical substances is one of the causes of occupation-related dental disorders. The present review aims to focus the attention of dental physicians towards this important problem.

KEYWORDS: occupational hazards; dentistry; biohazards; occupational diseases.


REFERENCES
1.Scott, S., De Rossi, D.M.D., Martin, S., Greenberg, D.D.S.: Intraoral contact allergy: a literature review and case reports, J. Am. Dent. Assoc., Vol. 129, pp. 14351-1441, 1998.
2.Guin, J.D.: Eyelid dermatitis from methacrylates used for nail enhacement. Contact Dermatitis, Vol. 39,pp. 312-313, 1998.
3.Fowler, J.F.: Late patch test reaction to acrylates in a dental worker, Am. J. Contact Dermat., Vol. 10, pp.224-225, 1999.
4.Lonnroth, E.C., Shahnavaz, H.: Use of polymer materials in dental clinics. Swed. Dent. J., Vol. 21, pp.149-150, 1997.
5.Bentley CD, Burkhart NW, Crawford JJ: Evaluating spatter and aerosol contamination during dental procedures. J Am Dent Assoc. 1994; 125:579-584.
6.Nimmo A, Werley MS, Martin JS, Tansy MF: Particulate inhalation during the removal of amalgam restorations. J Prosthet Dent. 1990;63:228-233.
7.Lan, Fu JS. Undue absorption of lead among children. A new look at an  old problem. New Eng J Med. 1972; 266: 702-10.
8.International Lobour Organization (ILO). Encyclopedia of occupational health and safety. 3rd ed. Geneva: ILO. 1983;1408-10.
9.Johansson AK. On dental erosion and associated factors. Swed Dent J  Suppl. 2002;1–77.
10.Darby ML, Walsh MM, editors. Dental hygiene theory and practice. 1st ed.  Philadelphia; WB Saynders Company. 1994.  p. 335-365.
11.Charpin D, Vervolet D: Epidemiology of immediate-type allergic reactions to latex. Clin Rev Allergy 1993, 11, 385-390.
12.Fisher AA: Contact urticaria and anaphylactoid reaction due to cornstarch surgical glove powder.  Contact Dermatitis. 1987;16:244-245.
13.Turjanamaa K, Alenius H, Mäkinen-Kiljunen S, Reunala T, Palosuo T: Natural rubber latex allergy. Allergy. 1996;51:593-602.
14.Tarlo SM, Sussman G, Contala A, Swanson MC: Control of  airborne latex by use of powder-free gloves.  J Allergy Clin Immunol1994, 93, 985-989.
15.Pretorius, E., Bester, M.J.: What every healt worker should know: the allergic potentional of surgical gloves. Southern African Journal of Epidemiology and Infection, Vol. 15, pp. 43-45, 2000.
16.Rustemayer, T., de Groot, J., von Blomberg, B.M.: Cross-reactivity paternsof contact-sensitizing methacrylates, Toxikology & Applied Pharmacology., Vol. 148, pp. 83-90, 1998.
17.Kanerva, L., Estalender, T., Jolanki, R., Alanko, K.: False-negative patch test reactions due to a lower concentration of a patch test substances then declared, Contact Dermatitis, Vol. 42, pp. 289-291, 2000.
18.Davis MS: Variations in patients’ compliance with doctors’ orders: analysis of congruence between survey responses and results of empirical investigations. J Med Educ 1966; 41:1037-1048.
19.Hulka BS, Cassel JC, Kupper LL, Burdette JA: Communication, compliance, and concordance between physicians and patients with prescribed medications. Am J Public Health 1976, 66, 847-853.
20.Turgut R, Krüger W: Psychosozialer Ansatz für die Motiveerung  zu praventivem Zahngesundheitsverhalten. Dtsch Zahnarztl Z 1982;37: 569-571.
21.Corah NL, O’Shea RM, Bissell GD: The dentist - patient relationship: perceptions by patients of dentist behavior in relation to satisfaction ond anxiety. J Am Dent Assoc. 1985;111(3):443-446.
22.Corah NL, O’Shea RM, Bissell GD: The dentist - patient relationship: mutual perceptions and behaviours. J Am Dent Assoc 1986;113(2):253-255.
23.Gale EN, Carlsson SG, Eriksson A, Jontell M: Effects of dentist’s behavior on patient’s attitudes. J Am Dent Assoc 1984, 109, 3, 444-446.
24.Simon JF, Peltier B, Chambers D, Dower J: Dentists troubled by the administration of anesthetic injections: long-term stresses and effects. Quintessence Int 1994, 25, 641-646.
25.Rankin J, Harris M: A comparision of stress and coping in male and female dentists. J Dent Pract Admin 1990, 7, 166-172.
26.Lussi A, Hellwig E, Zero D, Jaeggi T. Erosive tooth wear: diagnosis, risk factors and
prevention. Am J Dent. 2006 Dec;19(6):319-25.
27.Zero DT, Lussi A. Erosion--chemical and biological factors of importance to the dental practitioner. Int Dent J. 2005;55(4 Suppl 1):285-90.
28.Meurman JH, ten Cate JM. Pathogenesis and modifying factors of dental erosion. Eur J Oral Sci. 1996 Apr;104(2(Pt 2)):199-206.
29.Vanuspong W, Eisenburger M, Addy M. Cervical tooth wear and sensitivity: erosion,softening and rehardening of dentine; effects of pH, time and ultrasonication. J Clin Periodontol. 2002 Apr;29(4):351-7.
30.Jarvinen V, Rytomaa I, Meurman JH. Location of dental erosion in a referred population. Caries Res. 1992;26(5):391-6.
31.Rundcrantz BL, Johnsson B, Moritz U: Cervical pain and discomfort among in dentist. Epidemiological, clinical and therapeutic aspects. Part 1. A survey of pain and discomfort. Swed Dent J. 1990;14:71-80.
32.Rundcrantz BL, Johnsson B, Moritz U: Pain and discomfort in the musculoskeletal system among dentists. A prospective study. Swed Dent J. 1991;15: 219-228.
33.Rundcrantz BL, Johnsson B, Moritz U, Roxendal G: Cervicobrachial disorders in dentists. A comparison between two kinds of physiotherapeutic interventions. Scand J Rehabil Med. 1991;23:11-17.
34.Milerad E, Ekenvall L: Symptoms of the neck and upper exteremities in dentitists. Scand J Work Environ Health 1990;16:129-134.
35.Ostrem CT: Carpal tunnel syndrome. A look at causes, symptoms, remedies. Dent Teamwork 1996; 9:11-15.
36.Best Practice Guidelines for Occupational Safety and Health in DENTAL THERAPY PRACTICE, Auckland Regional Dental Service, Waitemata District Health Board, August 2001.


Source of support: None

Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.

Copyright © 2014 Singh P, Gandotra A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Original article

Neelam Sharma^1,*, Anshul Jhanwar²


Affiliation:-
¹Assistant Professor, Department of Obstetrics & Gynecology, Jhalawar medical college, Jhalawar, Rajasthan, India
²Assistant Professor, Department of Pharmacology, Jhalawar medical college, Jhalawar, Rajasthan, India

The name of the department(s) and institution(s) to which the work should be attributed:
Department of Obstetrics & Gynecology, J.L.N. medical college, Ajmer, Rajasthan, India

Address reprint requests to
Dr. Anshul Jhanwar.
III/2,Doctor’s residence, Medical College Campus, Jhalawar, Rajasthan, India (Pin-326001)

Article citation:
Sharma N, Jhanwar A. To study the effect of Mifepristone-Misoprostol combination for first trimester abortion in cases with previously scarred uterus. J Pharm Biomed Sci 2014; 04(08):930-935. Available at www.jpbms.info

ABSTRACT
Introduction: In India to deal with unwanted pregnancy in the scarred uterus is thorny situation, since the caesarian section rate is increasing. Although most widely used method for terminating pregnancy is dilatation and evacuation but it increases morbidity and mortality by causing uterine perforation, serious hemorrhage and shock. Therefore medical abortion offers an advantageous alternative to surgical abortion.
Material and methods: Total one hundred and fifty patients were selected for the present prospective study and were divided randomly into two equal groups after fulfilling the inclusion and exclusion criteria. Both groups were given 200 mg Mifepristone followed by 800 µg Misoprostol after 48 hours. Group 1 consist of patients with previously scarred uterus. Group 2 consisted of patients with previously non-scarred uterus.
Results: Mean period of gestation in group 1 was 43.48 days and in group 2 was 43.81 days. Mean gravidity in group 1 was 3.24 and in group 2 was 3.17.Mean parity in group 1 was 2.2 while in group 2 was 2.14.Efficacy of procedure which was determined by the number of complete abortions in the group (92% in group 1 and 93.3% in group2.Minor side effects were seen in 21 % patients of group 1 as compared to 28% in group 2.
Conclusion: Both the groups who underwent medical abortion with mifepristone-misoprostol combination were found to be comparable in terms of efficacy, safety and acceptability for termination of pregnancy of gestational age upto 49 days.


KEYWORDS: Mifepristone, Misoprostol, Scarred uterus, Lower segment cesarean section. 


REFERENCES

1.Norman JE et al. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 1991; 338:1233-1236.
2.Abraham Debby et al. Mid trimester abortion in patients with a previous uterine scar. European Journal of Obst & Gyne 2003.
3.Maitre SC,Bouchard P,Spitz IM .Medical termination of pregnancy.N Engl.J Med 2000;342:946-56.
4.Wu Y,Medical progress in China-Family planning.Natl Med J China 1995;75(12):749-75.
5.Creinin MD. Medical abortion regimens. Historical contest and overview. Am J Obstet & Gynecol 2000; 183:53-59.
6.Belfort P,Pinotti JA,Eskes Tkab.Fertility,sterility and contraception. Caterton Hall, Carnforth, UK: The Parthenon Publishing Group.1989; 28-31.
7.Bygdeman M. Termination of pregnancy upto 8 or 9 weeks-Modern methods of inducing abortion. Black-well science:Oxford;1995:39-53
8.Sun H,Wu S,Xu H et. Al.The potential of Ru 486 for medical termination of pregnancy: An acceptability and feasibility study. J Repro Med (China). 1995; 4(3):749-75.
9.Coyaji K,Etul B,Krishna U,Otiv S, Ambardekar S,Bopardikar A: Mifepristone abortion outside the urban research hospital setting in India.Lancet,2001;357:120-22.
10.Brogden RN, Goa KL, Faulds D. Mifepristone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1993; 45:384-409.
11.Renee M, Hart S. Mifepristone: Annuals of pharmacotherapy 2001;35:707-15.
12.Robbins A,Spitz IM. Mifepristone clinical pharmacology. Clin Obstet Gynecol 1996;39:436-50.
13.Berghella V,Airoldi J. Misoprostol for first trimester pregnancy termination in women with prior cesarean;a systemic review. BJOG;May 2009.
14.Muhammad Fawzy. Mid trimester abortion using vaginal misoprostol for women with 3 or more prior cesarean deliveries. JJOG 2010 March.
15.Premila W,Prabath T. Factors affecting outcome of early medical abortion: A review of 4132 consecutive cases; BJOG: Nov 2002;109:1281-89.
16.J Xu, Chen H. Termination of early pregnancy in scarred uterus with mifepristone and misoprostol. IJOG.72 (2001):245-51.


Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patients and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.

Disclosure forms provided by the authors are available with the full text of this article at jpbms.info


Copyright © 2014 Sharma N, Jhanwar A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Original article


Sharmila ¹ MD (OBG), Sendhil Coumary.A^1* MD, DNB, MNAMS (OBG), Lopamudra B John^1† MD, DNB (OBG), Seetesh Ghose ^1¥ MD, FICOG


Affiliation:-
¹Assisstant Professor, ^*1Professor, ^1†Associate Professor, ^1¥Professor And Head Of Department, Department Of Obstetrics And Gynaecology, Mahatma Gandhi Medical College And Research Institute Pillaiyarkuppam Puducherry- 607402, India

The name of the department(s) and institution(s) to which the work should be attributed:
Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College and Research Institute, Puducherry, India

Address reprint requests to
Dr. Sendhil Coumary. A,
Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College And Research Institute, Pillaiyarkuppam, Puducherry, India-607402

Article citation:
Sharmila ,Coumary SA,John LB,Ghose S. Effectiveness of Intravenous Iron Sucrose among SouthIndian Antenatal Women. J Pharm Biomed Sci. 2014; 04(09):936-940. Available at www.jpbms.info

ABSTRACT
Objectives: The study aims to evaluate the safety and efficacy of intravenous iron sucrose among south indian antenatal women with moderate iron deficiency anaemia in the second trimester not responding to oral iron.
Methods: The study was a prospective interventional study conducted in the department of obstetrics and gynaecology at MGMCRI, Pondicherry, South India.  During a study period of 18 months starting from December 2011, a total of 61 antenatal women were included in the study. 32 received intravenous iron sucrose in divided doses, as they did not respond well to oral iron. Haemoglobin, PCV and serum ferritin were measured before and after intra venous sucrose. The results were tabulated and analysed.
Results: After oral iron therapy the mean haemoglobin was 8.97 ± 0.80 gm%, the mean PCV was  28.16 ± 2.6,  and the mean serum ferritin was 13.32 ± 2.49 micrograms  respectively. After IV iron sucrose therapy the mean haemoglobin was 10.15 ± 0.36, the mean PCV was 31.5± 2.10 and the mean serum ferritin was 44.09± 7.02 respectively. There was a statistically significant difference in the rise of mean haemoglobin, PCV and serum ferritin after therapy with iron sucrose. There were no significant side effects related to intravenous iron sucrose therapy.
Conclusion: Iron sucrose is safe and effective without any serious side effects in correcting the iron deficiency anemia in pregnancy among those who are not responding or intolerant to oral iron.

KEYWORDS: Iron sucrose; iron deficiency anemia; antenatal women.

Source of support: None

Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.

REFERENCES
1.Nutritional anemia during pregnancy in non industrialised countries in Progress in Obstetrics and Gynaecology 15. Studd J, Tan S L, Frank A. Chervenak. 2003; 8 (1): 103-121.
2.Aykut Barut, Mehmet Harma Intravenous iron treatment for iron deficiency anemia in pregnancy. J Turkish-German Gynecol Assoc 2009;10: 109-15
3.Alhossain A. Khalafallah, Amanda E. Dennis Iron deficiency anemia in pregnancy and postpartum : pathophysiology and effect of oral versus intravenous iron therapy. Journal of pregnancy Volume 2012 doi:10.1155/2012/630519
4.Arnoff GR, Bennett WM, Blumenthal S et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004;66:1193-98
5.Ragip A Al, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, and Haberal A. Intravenous versus oral Iron in the treatment of  anemia in pregnancy. The American College of Obstetricians and Gynaecologists, 2005; 106(6) : 1335-40.
6.Naz N, Mashoori R G, Zehra T, Chaudhry A, Laghari J. Intravenous Iron Sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy. Medical Channel 2008 Mar ; 14(1): 55-58.
7.Shafi D, Purandare SV, Sathe AV. Iron deficiency anemia in pregnancy: intravenous versus oral route. J Obstet Gynaecol India. 2012 Jun;62(3):317-21. doi: 10.1007/s13224-012-0222-0. Epub 2012 Aug 1.
8.Deepti S, Sunetra I, Sindhu B, Amreen S. Effectiveness of Intravenous Iron Sucrose in Management Of Iron Deficient Anemia of Pregnancy at Rural Hospital Set Up. Journal of Obstetrics and Gynaecology of India 2012 Apr; 62(2): 154-157.


Copyright © 2014  Sharmila ,Coumary SA,John LB,Ghose S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.